In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
Hosted on MSN17d
I will find the strength to tackle my cancer in 2025 - Mel O'Neill
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...
BioWorld29d
Taiwan’s Tanvex receives second CRL for Herceptin biosimilar
Tanvex Biopharma Inc. said its U.S. subsidiary, Tanvex Biopharma U.S.A. Inc., received an FDA complete response letter (CRL) on Jan. 3 for its TX-05 BLA, a biosimilar that references Roche AG’s ...
clinicaladvisor.com29d
Prostate Cancer Treatment Challenge: Which Drugs to Use First
Among the overarching trends is earlier and earlier treatment intensification to forestall development of metastases and castration-resistant prostate cancer (CRPC). Triplet therapy with docetaxel ...